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Abstract
Introduction: This study describes quality indicators for the pre-analytical process, grouping errors according to patient risk as critical or major, and 
assesses their evaluation over a five-year period.
Materials and methods: A descriptive study was made of the temporal evolution of quality indicators, with a study population of 751,441 anal-
ytical requests made during the period 2007-2011. The Runs Test for randomness was calculated to assess changes in the trend of the series, and the 
degree of control over the process was estimated by the Six Sigma scale.
Results: The overall rate of critical pre-analytical errors was 0.047%, with a Six Sigma value of 4.9. The total rate of sampling errors in the study pe-
riod was 13.54% (P = 0.003). The highest rates were found for the indicators “haemolysed sample” (8.76%), “urine sample not submitted” (1.66%) 
and “clotted sample” (1.41%), with Six Sigma values of 3.7, 3.7 and 2.9, respectively.
Conclusions: The magnitude of pre-analytical errors was accurately valued. While processes that triggered critical errors are well controlled, the 
results obtained for those regarding specimen collection are borderline unacceptable; this is particularly so for the indicator “haemolysed sample”.
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Introduction
Strategies in the field of risk management and pa-
tient safety are aimed at the prevention, detection 
and mitigation of adverse events through the anal-
ysis of errors. In the clinical laboratory all errors 
must be measured and controlled, from the obvi-
ous ones to those that do not originate in the lab-
oratory (1), by means of indicators providing an 
objective assessment of the problem and, when 
appropriate, by carrying out comparisons between 
different laboratories and different periods of time. 
According to point 4.12.4 of ISO 15189, “Medical 
laboratories – particular requirements for quality 
and competence”, laboratory managers should 
implement quality indicators for the systematic 
monitoring and evaluation of the laboratory’s con-
tribution to patient care (2). Moreover, the Europe-
an Committee of Experts on Management of Safe-
ty and Quality in Health Care has proposed that 
indicators should be useful, identify the critical 
steps in each process, reflect their potential and 
make it possible to continuously assess safety in 
healthcare procedures, in order to accredit sus-
tained improvement and to determine when defi-
ciencies occur (3).
Since the 1960s, with the introduction of analytical 
quality control, the approach taken to ensuring 
quality has evolved, focusing in turn on concepts 
such as quality guarantees, the management of 
quality, the use of quality goals, the specification 
of operational processes and of the resources 
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needed to meet the objectives of the system (4) 
and total quality management, to the more recent 
focus on clinical safety and risk management (5-8). 
From this standpoint, Technical Specification ISO/
TS 22367, “Medical laboratories. Reduction of error 
through risk management and continual improve-
ment” was developed to indicate how risk man-
agement should be implemented in the structure, 
organisation, operation and quality management 
system of the clinical laboratory, with special em-
phasis on the pre and post-analytical phases (9).
Of the three key processes in the clinical laborato-
ry, the analytical phase is the most highly stand-
ardised, with well-defined indicators and interna-
tionally-accepted specifications for a large number 
of biological magnitudes (10-12). All studies agree 
that it is in the extra-analytical processes where 
the greatest number of errors occur, especially in 
the pre-analytical stage. These processes, moreo-
ver, are the most critical (13-15) and the hardest to 
manage, due to the decentralisation of extractions, 
involving the participation of various professionals 
(physicians, specialists of laboratory medicine, 
nurses, laboratory technologists and technicians, 
phlebotomists etc.), organisations and healthcare 
centres.
In this study we describe quality indicators of the 
pre-analytical process, grouping errors according 
to patient risk as critical or major, and assess their 
evaluation over a five-year period.
Material and methods
Design
A descriptive study was carried out of the tempo-
ral evolution of the pre-analytical quality indica-
tors proposed for monitoring clinical risk, at the 
Clinical Laboratory of Antequera Hospital.
Data source
The study population was constituted of all the 
analytical requests received by the laboratory (no 
exclusion criteria were applied) from primary 
healthcare providers (approximately 41%), special-
ists (33%), hospital inpatient departments (6%) and 
accident and emergency departments (20%), dur-
ing the period 2007-2011, inclusive.
The Clinical Laboratory of Antequera Hospital is a 
Clinical Management Unit, certified in accordance 
with ISO 9001:2008, and by the Andalusian Agency 
for Healthcare Quality, Advanced level. It provides 
the specialised services of clinical biochemistry (4 
physicians), microbiology (1 physician) and haema-
tology (3 physicians), assisted by 21 technical and 
3 administrative staff, using a laboratory informa-
tion system (LIS) with no electronic request facility 
(Open for Labs ®). It is organised into working units 
according to the technology involved, with a cen-
tral laboratory that carries out both scheduled and 
urgent tasks. This laboratory is equipped with 2 
haematology cell counters, 2 automated haemos-
tasis analysers, 2 biochemistry analysers and 2 an-
alysers for immunochemical techniques, with no 
pre-analytical automation. In addition, the bio-
chemical area has an automated urinalysis system, 
two blood gas analysers and an osmometer. A spe-
cial technical unit performs the analyses for stud-
ies of allergies and autoimmune diseases, using an 
automated system for autoimmunity and allergy, 
and seminal fluids.
The laboratory attends a population of 115,155 in-
habitants (2010 census), divided among four Basic 
Health Areas with 19 Clinics and Neighbourhood 
Clinical Sampling Centres. In 2011, it received 
155,999 requests for analysis, giving rise to 
1,628,852 individual results. All clinical samples, 
both in hospitals and in primary healthcare, are 
taken by external nursing staff, unrelated to the 
laboratory, and all specimens are centrifuged at 
the primary healthcare centre before their transfer 
to the laboratory. The centrifugation process is su-
pervised by the nursing department at the centre.
The indicators were designed in 2006 following a 
descriptive Modal Failure and Effects Analysis 
(MFEA), carried out as an integral part of the pre-
analytical phase, a process in which the Neigh-
bourhood Clinical Sampling Centres were includ-
ed. This analysis made it possible to define the crit-
ical steps in clinical sampling processes that can 
lead to mistakes being made, thus enabling cir-
cuits to be redesigned and procedures restruc-
tured. In this analysis, mistakes are classified in ac-
cordance with the corresponding Risk Priority 
Number (RPN), which enables us to prioritise those 
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to be monitored. This number is obtained by mul-
tiplying the scores given to evaluate the frequency 
of occurrence of the error and its severity (on a 
scale of 1 to 10, from least to most frequent/se-
vere) and the probability of error detection (on an 
inverse scale, from 10: low probability to 1: high 
probability).
Three main categories of mistake were identified: 
“critical” mistakes (RPN > 500), arising mainly from 
the type of analytical request and the means used 
to communicate and record it, with severe conse-
quences for the patient if not rapidly detected and 
corrected (16); “major” ones, arising from inade-
quate application of the sampling procedure (RPN: 
112-315); and “minor” ones, considered as such due 
to the low likelihood of their occurrence, high 
probability of detection or absence of severity 
(RPN < 100). These latter mistakes were only taken 
into account for the purposes of reviewing proce-
dures and technical instructions (17). This analyti-
cal tool has its limitations, especially in the health-
care context, because it is designed for industrial 
use before a product is marketed; in any case, any 
critical error should be seen as such regardless of 
the NPR value determined. The project was ap-
proved by the laboratory’s senior management.
To ensure ongoing improvement, it is of funda-
mental importance to provide training in safety 
procedures. For this reason, accredited courses 
were given to laboratory staff in 2008, 2009 and 
2010. In the latter year, the course was oriented to-
ward transfusion safety, while practical sessions 
for nursing staff in specimen-taking procedures 
were organised in 2009. It is essential for staff to 
actively learn from mistakes, and so the indicator 
results are reported to the services involved every 
three months. An annual retrospective analysis is 
made of the results, and this is published in the 
corresponding management report.
Outcome variables: indicators
Critical error in patient identification, when ad-•	
ministrative staff manually enters the analytical 
request into the LIS.
Critical errors that could compromise patient •	
safety, recorded by a notice of non-conformity. 
Such errors might originate outside the labora-
tory (a request in which the patient is incorrect-
ly identified and/or the sample presents such a 
misidentification) or within it, due to an identifi-
cation error in producing the aliquot.
Total rate of critical errors.•	
Haemolysed sample: for both serum and plas-•	
ma samples, any degree of haemolysis from 
‘slightly haemolysed’ to ‘highly haemolysed’, is 
logged as ‘haemolysed sample’, by direct ob-
servation and checking against a colorimetric 
table published by the Spanish Society for Clin-
ical Chemistry, which expresses the equivalent 
of a haemoglobin concentration ranging from 
0 (absence of haemolysis) to 10 g/L.
Clotted sample: in blood with ethylenediami-•	
netetraacetic acid (EDTA) or with sodium citrate, 
by direct observation in the presence of coagu-
lation.
Inadequate sample container (refers to any type •	
of sample).
Insufficient sample (refers to any type of sam-•	
ple).
Blood sample not submitted.•	
Urine sample not submitted.•	
Total rate of major errors.•	
Data collection
To compile data on critical errors, a database was 
designed to record the errors occurring in the lab-
oratory, when analytical requests are manually en-
tered into the LIS. Such errors are expected to 
cease when an electronic request system is imple-
mented. These errors are currently detected either 
when the healthcare clinic requests an analytical 
report that cannot be found, or when primary 
healthcare centres check the analytical reports re-
ceived against the lists of patients who provided 
clinical samples. A second data recording system 
used, for any type of critical error detected in the 
laboratory (in the present context, pre-analytical 
and other than those mentioned above), is initiat-
ed by means of a notice of “non-conformity” (18). 
Such errors may be detected by the analyst on 
checking the report, or also by the physician, on 
observing that the details do not correspond to 
the clinical data, and are communicated to the lab-
oratory. In either case, a procedure has been im-
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plemented to declare and record such events, via 
the quality manager or the laboratory manage-
ment system.
All errors related to the absence of sample quality 
are entered into the LIS directly by the laboratory 
staff, on receipt of the sample, and are appropri-
ately described by reference to a thesaurus previ-
ously created for this purpose. During the study 
period, the data-compilation methodology re-
mained unchanged.
Statistical analysis
Quarterly rates were calculated for the proposed 
indicators, with their respective mean values, com-
pared to the total volume of activity, in terms of 
analytical requests. The formulas used for the cal-
culations are summarised in Table 1. The Runs Test 
was applied to assess changes in the trend of the 
series, assuming statistical significance at P < 0.050. 
To determine the annual volume of requests and 
statistically significant indicators according to the 
Runs Test, the base 100 index was calculated with 
respect to the first year (or quarter) valued, and 
these indicators were represented by frequency 
polygons. To estimate the degree of control over 
the processes, the results were transformed ac-
cording to the Six Sigma scale, using the Westgard 
calculator (19), thus obtaining the frequency with 
which an error is likely to occur. According to the 
table of equivalence between the Sigma level and 
defects per million, an error rate of 6.68% corre-
sponds to a Sigma value 3, equivalent to border-
line unacceptable, while an error rate of 0.62% cor-
responds to a Sigma value 4, which reflects a good 
level of control (19,20).
Results
A total of 751,441 analytical requests were made to 
the Laboratory Service between 2007 and 2011. 
For the study period, comprehensive information 
was obtained on all the proposed quality indica-
tors, except for one critical error which was record-
ed as a non-conformity notice, and not quantified 
in 2007. In 2007, there were 141,561 requests, and 
the volume increased by over 10% each year after 
this. The rates obtained for each indicator, the to-
tal sampling errors for the study period and the P-
value for the Runs Test are summarised in Table 2. 
Table 3 shows the Six Sigma values and the aver-
age for each indicator.
Pre-analytical critical error indicator
The total rate of pre-analytical critical errors was 
0.047%, obtained from the average non-conformi-
ty critical error of 0.022% (since 2008), and the val-
ue of 0.028% of errors in data entered into the LIS. 
The Runs Test reflected no changes in the trend 
for either type of error. According to the Westgard 
calculator this error rate corresponds to a Sigma 
Six value of 4.9.
Indicator Formula
Haemolysed sample Number of haemolysed samples x 100 / Total number of requests
Clotted sample Number of clotted samples x 100 / Total number of requests
Inadequate container Number of inadequate containers for each sample type x 100 / Total number of requests
Insufficient sample Number of insufficient samples for each sample type x 100 / Total number of requests
Blood sample not submitted Number of samples with no blood sent x 100 / Total number of requests
Urine sample not submitted Number of samples with no urine sent x 100 / Total number of requests
Total sample incidents Total number of sample quality incidents x 100 / Total number of requests
Critical error “Non conformity” Number of non-conformities x 100 / Total number of requests
Critical error: entry of requests into LIS Number of LIS critical errors x 100 / Total number of requests
Total critical errors Total number of non-conformities + Critical LIS errors x 100 / Total number of requests
Table 1. Formulas for calculation of pre-analytical indicators.
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2007-1 36,420 9.26 1.56 0.11 0.43 1.24 2.14 14.74 0.055
2007-2 36,587 7.66 1.28 0.14 0.28 1.22 1.73 12.30 0.025
2007-3 32,812 8.31 1.80 0.11 0.25 1.44 1.64 13.55 0.037
2007-4 35,742 9.12 1.79 0.14 0.40 1.58 1.51 14.54 0.053
2008-1 37,340 11.90 1.93 0.11 0.52 1.42 1.63 17.50 0.024 0.035 0.059
2008-2 39,747 10.29 1.34 0.10 0.34 1.32 1.56 14.96 0.033 0.045 0.078
2008-3 34,716 10.38 1.59 0.06 0.41 1.20 1.79 15.42 0.023 0.009 0.032
2008-4 37,708 10.78 1.61 0.05 0.33 1.33 1.88 15.98 0.019 0.037 0.056
2009-1 40,554 13.44 1.62 0.10 0.40 1.45 1.73 18.75 0.015 0.015 0.030
2009-2 40,071 10.34 1.35 0.11 0.39 1.39 1.75 15.33 0.017 0.042 0.060
2009-3 34,906 7.68 1.25 0.05 0.49 1.41 1.64 12.53 0.017 0.017 0.034
2009-4 37,871 7.39 1.19 0.04 0.41 1.32 1.61 11.97 0.024 0.050 0.074
2010-1 39,496 7.64 1.22 0.04 0.39 1.11 1.71 12.11 0.013 0.020 0.033
2010-2 39,750 5.85 1.15 0.06 0.27 1.03 1.40 9.76 0.030 0.023 0.053
2010-3 34,700 5.65 1.46 0.07 0.33 1.19 1.53 10.22 0.026 0.012 0.037
2010-4 37,111 7.60 1.24 0.05 0.26 1.28 1.46 11.90 0.019 0.013 0.032
2011-1 40,803 8.19 1.17 0.05 0.28 1.06 1.70 12.45 0.039 0.020 0.059
2011-2 41,617 8.24 1.01 0.06 0.19 1.18 1.73 12.41 0.024 0.036 0.060
2011-3 35,773 7.68 1.40 0.05 0.26 1.43 1.49 12.30 0.011 0.011 0.022
2011-4 37,717 7.28 1.42 0.03 0.35 1.48 1.52 12.09 0.016 0.011 0.027
TOTAL/
Mean 751,441 8.76 1.41 0.08 0.35 1.30 1.66 13.54 0.022 0.028 0.047
P* 0.039 0.491 0.314 0.491 0.041 0.265 0.003 0.578 0.619 0.196
Pre-analytical indicators are presented as a frequency of total number of requests; *P value of Runs Test.
Table 2. Quarterly rates of pre-analytical indicators.
Of the 134 non-conformity errors reported, 50.74% 
of the samples did not correspond to the patient 
described in the analytical request, while 44.03% 
of the samples corresponded to an error made by 
the physician in formulating the analytical request. 
All of these errors remained undetected by the 
nursing staff, who failed to confirm the identity of 
the patient before performing the extraction. In 
one case, a sample required for judicial proceed-
ings was invalidated by incorrect collection, and 
on three occasions results were found to be con-
taminated (one with EDTA and the other two with 
glucosaline solution from the sampling apparatus). 
The remaining three cases originated in the labo-
ratory: twice, samples from different paediatric pa-
tients were combined in order to obtain a greater 
sample volume, and once, an error arose in the 
manual preparation of the sample aliquot.
Indicators related to specimen-collection 
errors
The total error rate for the study period was 
13.54%, with a P-value for the Runs Test of 0.003. 
The lowest rate per 100 requests was for the indi-
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cator “inadequate container” (0.08%) followed by 
“insufficient sample” (0.35%), while the highest 
rates corresponded to the indicators “haemolysed 
sample” (8.76%), “urine sample not submitted” 
(1.66%) and “clotted sample” (1.41%).
Statistically significant differences were identified 
by the Runs Test, in addition to the total rate of in-
cidents, for the indicators “haemolysed sample” 
and “blood sample not submitted”, both at P = 
0.039, and the total rate of errors decreased appre-
ciably from the second quarter of 2009 (Figure 1).
Translated into Sigma metrics, the error rate was 
2.7%, fundamentally regarding the indicator 
“haemolysed sample”, with a Sigma Six value of 
2.9. For the remaining processes, the Sigma values 
ranged from 3.7 (“clotted sample”) to 4.7 (‘inade-
quate container”).
Discussion
A precise calculation was made of the magnitude 
of the pre-analytical errors associated with our ac-
tivity and area of organisation, after implementing 
a FMEA, during the period 2007-11. This analysis 
considered, first, critical errors, i.e., those which 
could lead to the analytical report being assigned 
to another patient or to erroneous results being 
reported, thereby provoking a misdiagnosis or in-
correct treatment decisions being established, as a 
result of the procedure and the means by which 
analytical requests are made and entered into the 
system. A second group of errors, arising from mal-
practice in the specimen collection procedure, and 
considered “major” insofar as they affect analytical 
quality, cause delays, require additional or repeat-
ed analyses and increase costs.
Year 2007 2008 2009 2010 2011 Total
Indicator N 6 Sigma N 6 Sigma N 6 Sigma N 6 Sigma N 6 Sigma N 6 Sigma
Haemolysed 12,161 2.90 16,202 2.80 15,075 2.80 10127 3.00 12,262 3.00 65,827 2.90
Clotted 2264 3.70 2410 3.70 2090 3.80 1907 3.80 1937 3.80 10,608 3.70
Inadequate container 176 4.60 121 4.70 118 4.70 79 4.80 73 4.90 567 4.70
Insufficient sample 483 4.30 596 4.20 643 4.20 471 4.30 422 4.30 2615 4.20
No blood sample sent 1940 3.80 1972 3.80 2138 3.70 1734 3.80 1993 3.80 9777 3.80
No urine sample sent 2487 3.70 2561 3.70 2588 3.70 2307 3.70 2518 3.70 12,461 3.70
Total incidents 19,511 2.60 23,862 2.50 22,652 2.60 16,625 2.80 19,205 2.70 101,855 2.70
Non-Cfty critical error 37  28  33  36    
LIS critical error 60  48  48  26  31  213  
Total critical errors  85 4.80 76 4.80 59 4.90 67 4.90 287 4.90
Total requests 141,561 100* 149,511 105.62* 153,402 108.36* 151,057 106.71* 155,910 110.14* 751,441  
*Requests (Base 100 = 2007)








































































Figure 1. Quarterly total rate of major errors (rate per 100 re-
quests).
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The issue of pre-analytical quality indicators is not 
a novel one, but this study proposes an innovative 
approach to developing such indicators and defin-
ing their scope, in accordance with the recommen-
dations of the European Committee of Experts on 
Management of Safety and Quality in Health Care 
(3), the requirements of ISO 15189 (2), and the 
methodology proposed in the Technical Specifica-
tion ISO 22367:2008. (9) To the best of our knowl-
edge, no previous study has been made to moni-
tor pre-analytical errors after the implementation 
of a FMEA. Perhaps the main contribution of the 
present study is its scope: the fact that it has incor-
porated all the processes involved, in the hospital 
and in primary health care, taking into account the 
multidisciplinary professionals involved in the 
process of obtaining analytical samples, and ad-
dressing all areas relevant to the clinical laboratory. 
Moreover, the study design is highly effective. We 
propose a prior descriptive analysis that achieves 
high sensitivity and controls the efficiency of the 
process, in contrast to a record of predefined or 
fortuitous errors that presents low sensitivity; this 
latter approach only ensures good results with re-
spect to individual activities, and provides little or 
no overall control of the process (21).
Indeed, measuring and managing pre-analytical 
critical errors continues to be the major challenge 
facing clinical laboratories (7,8,22,23), and the main 
difficulty in this respect lies in achieving an effec-
tive, systematic design to ensure that safe proce-
dures and processes are adopted, accompanied by 
all necessary corrective procedures (3,24). Many 
factors affect patient safety and many variables af-
fect each of the sub-processes, services and health-
care professionals involved in the pre-analytical 
process. This complexity makes it difficult to man-
age pre-analytical critical error, and is one reason 
why the scientific literature in this respect provides 
very limited data, being focused more on estimat-
ing the frequency and specifications of errors re-
lated to sample quality than on examining those 
which are potentially critical. In general, insuffi-
cient attention is paid to such errors, as regards 
their impact on health care (13-15,23). Analysis of 
our results revealed relatively few “critical errors” 
compared with previously published data, and 
these corresponded to the terms “error in patient 
identification in inputting data to the LIS”, “patient 
name incorrect on the request” or “no specimen/
analytical request traceability” (13,14,25-29), al-
though these studies are methodologically differ-
ent. It is unrealistic to believe that all critical errors 
are recorded, but all healthcare centres check their 
lists against analytical requests and we analysed 
all analytical incidents in search of possible errors. 
Furthermore, the act of recording them, as pro-
posed in Technical Specification ISO/TS 22367, 
through the creation of a “non-conformity” notice 
(9), means they can be investigated on an individu-
al basis, to analyse the cause and the potential 
harm to the patient, and to take preventive and 
corrective measures.
It is essential to learn from mistakes, and for this 
reason a quarterly report of the results of the indi-
cators is communicated to senior management, to 
the medical officers, to the hospital’s quality con-
trollers, to the heads of unit (in hospitals and pri-
mary care) and to nursing managers. These activi-
ties, together with the laboratory’s policy of always 
rejecting doubtful samples, and in such cases de-
manding a new sample request and specimen col-
lection, has led to the establishment of a culture 
oriented toward safety and the recognition of er-
rors committed. It is beyond the scope of this study 
to investigate possible harm caused to the pa-
tient.
After application of FMEA to obtain suitable indi-
cators, the Sigma methodology was used as a sta-
tistical tool to quantify the results, expressed as 
defects per million opportunities (30,31), to evalu-
ate the effectiveness of the training and informa-
tion actions aimed at improving the system and to 
compare them with the standards proposed by 
Llopis et al. (27) and with the preliminary data on 
quality indicators obtained by the IFCC Working 
Group Project “Laboratory Errors and Patient Safe-
ty” (32).
For critical errors, we obtained a Sigma value of 
4.9, which indicates that the processes involved 
are well controlled. However, as suggested by 
Llopis et al. (27), given the potential danger to the 
patient of such incidents, their specification should 
http://dx.doi.org/10.11613/BM.2014.027 Biochemia Medica 2014;24(2):248–57 
  255
Giménez-Marín A. et al. Pre-analytical errors management in the clinical laboratory
be 0%, equivalent to a Sigma value of 6. In this re-
spect, there were differences in the type of indica-
tors used. In contrast to those proposed in the 
above-mentioned studies, which focus more on 
quality or compliance with minimum requirements 
for analytical requests, in the present study, which 
is aimed at measuring the risk of critical error in 
our pre-analytical process, the indicators used are 
the result of an initial determination of what steps 
in the processes are to be measured, how and 
when. These questions are then prioritised accord-
ing to the level of risk.
In monitoring specimen collection, it is logical to 
use the percentage of total error for which a bad 
result is obtained, mainly caused by the indicator 
“haemolysed sample”. This means that the process 
is borderline unacceptable and requires a thor-
ough review.
In this study, the criteria for deciding which indica-
tors should be monitored are determined by the 
MFEA, specifically, by the NPR values obtained, re-
gardless of any preanalytical incident that may be 
recorded in the analytical report. Comparison with 
the results of Llopis et al. (27) shows that it is in 
haemolysis where we are still far from reaching the 
specifications stipulated. In (27), the largest group 
of laboratories used the same method of visual in-
spection, and it is not stated what minimum de-
gree of haemolysis is recorded. A limiting factor of 
our study, as regards comparison with previous re-
search, is the fact that our results are expressed as 
a percentage of analytical requests, whether se-
rum or coagulation tube in the absence of a sys-
tem enabling us to count the number of tubes, 
and that only a single analytical request form was 
available for all areas of knowledge.
Moreover, in the case of haemolysis, due to the ab-
sence of recommendations as to the minimum de-
gree of haemolysis that should be recorded, our 
study used a single heading “haemolysed sample”. 
Nevertheless, the analytical report specified any 
degree of haemolysis detected, regardless of 
whether it interfered to a greater or lesser extent 
with the analysis of the analyte and whether or not 
the test was invalidated in strongly haemolysed 
samples. This may compensate, to some degree, 
for the bias arising from the subjective determina-
tion performed, based on visual inspection, and 
not on the determination of an index of haemoly-
sis using the automated clinical chemistry system. 
This is a limitation of our study. However, the latest 
recommendations for improving the assessment 
of this indicator specify how haemolysis should be 
identified and quantified and what threshold 
should be used for rejecting the sample, express-
ing the indicator in terms of the total number of 
samples (32). In our study, this indicator produces 
overvalued results, fundamentally because it 
counts all stages of haemolysis, and in conse-
quence 25% of the comments made lead to the 
test being invalidated. The main cause of the high 
rate of in vitro haemolysis in our context is multi-
factorial: a) in general, serum rather than plasma is 
employed; b) the vacuum system is not widely 
used, the specimen tubes being filled directly us-
ing a syringe (33); c) staff are insufficiently skilled in 
the sampling process.
Our review of the literature revealed different ways 
by which this type of indicator could be formulat-
ed, but these proposals are not comparable with 
our results, because in some cases they refer to the 
total number of tests performed (13,15,23), and this 
type of indicator will always achieve better results 
when larger magnitudes are involved and when 
analytical correctness is less well managed. In oth-
er cases, which are more recent and more accu-
rate, they are not comparable because they refer 
to the total number of samples obtained (28,29,32). 
All the studies reviewed agree that the problems 
associated with obtaining specimens are the lead-
ing cause of pre-analytical errors, with haemolysis 
presenting greatest variability and comprising the 
most frequent cause of sample rejection 
(13,23,27,34,35). Plebani et al. highlighted the ur-
gent need to harmonise quality indicators, in view 
of how they can be affected by different interpre-
tations and how they are measured by each labo-
ratory. These indicators are subject to three main 
requirements: they must be patient-centred, con-
sistent with the requirements of the International 
Standard for medical laboratories accreditation, 
and address all stages of the total testing process. 
(36).
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In future studies we will consolidate this approach 
and analyse the changes presented by the indica-
tors after the implementation of definitive forms 
of improvement and after investigating the possi-
ble harm to the patient and the inefficiency costs 
generated by such errors.
Conclusions
This paper presents a rigorous, patient-centred 
analysis of the magnitude of pre-analytical errors, 
in accordance with the requirements of the Inter-
national Standard for medical laboratories accredi-
tation, incorporating all the sub-processes and 
personnel involved in the pre-analytical process. 
The processes that trigger “critical” errors, while 
not achieving the zero-error level, are well control-
led, and errors in the sample-taking process are of 
only marginal importance, mainly concerning the 
indicator “haemolysed sample”.
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